Spark Therapeutics 2017 Cowen Health Care Conference

Spark Therapeutics presented its validated gene therapy platform at the Cowen Health Care Conference, showcasing human proof-of-concept data for voretigene neparvovec in inherited retinal disease and SPK-9001 in hemophilia B. The company highlighted breakthrough therapy designations, preliminary clinical data demonstrating efficacy and durability, and a rolling BLA submission targeting 2017 FDA approval.